Compare BTQ & BBNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BTQ | BBNX |
|---|---|---|
| Founded | 1983 | 2015 |
| Country | Canada | United States |
| Employees | 27 | 423 |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 448.1M | 493.1M |
| IPO Year | N/A | N/A |
| Metric | BTQ | BBNX |
|---|---|---|
| Price | $3.52 | $13.04 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 9 |
| Target Price | $10.00 | ★ $24.00 |
| AVG Volume (30 Days) | ★ 2.3M | 1.1M |
| Earning Date | 03-31-2026 | 04-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $2,332.99 | $34.90 |
| Revenue Next Year | N/A | $34.63 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.09 | $8.80 |
| 52 Week High | $16.00 | $32.71 |
| Indicator | BTQ | BBNX |
|---|---|---|
| Relative Strength Index (RSI) | 66.07 | 62.07 |
| Support Level | $2.23 | $12.10 |
| Resistance Level | $3.83 | $15.53 |
| Average True Range (ATR) | 0.30 | 0.97 |
| MACD | 0.17 | 0.47 |
| Stochastic Oscillator | 82.57 | 92.26 |
BTQ Technologies Corp is engaged in the development of computer-based technology related to post-quantum cryptography, particularly as it applies to blockchain and related technologies, and their protection from the emerging security risk of quantum computing. Its products include PQScale, Keelung, Kenting, and Qbyte. PQScale is a novel scaling technique for post-quantum cryptographic primitives. Keelung is a zero-knowledge toolkit for fast, private, and secure applications. Kenting provides acceleration for NIST-compliant post-quantum cryptography, post-quantum zk-SNARKs, and eco-friendly mining hardware, and Qbyte is a quantum risk calculator. Geographically, the company derives maximum revenue from Canada, and also has a presence in Taiwan, and Australia.
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.